Joinn Laboratories(China)Co.,Ltd.
603127
Rang in Aktien
#3819
Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of... Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
Aktienkurs
$6.82
Marktkapitalisierung
$4.30B
Veränderung (1 Tag)
-6.30%
Veränderung (1 Jahr)
48.79%
Land
CN
Handel Joinn Laboratories(China)Co.,Ltd. (603127)
Kategorie
Healthcare
Gewinn für Joinn Laboratories(China)Co.,Ltd. (603127)
Gewinn im Jun 2026 TTM: $160.62M
Laut den aktuellen Finanzberichten von Joinn Laboratories(China)Co.,Ltd. betragen die aktuellen Gewinne des Unternehmens $160.62M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $14.25M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $71.62M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Joinn Laboratories(China)Co.,Ltd. von 2012 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $160.62M | 232.97% |
| 2025 | $48.24M | 238.43% |
| 2024 | $14.25M | -80.10% |
| 2023 | $71.62M | -60.16% |
| 2022 | $179.77M | 77.97% |
| 2021 | $101.01M | 83.00% |
| 2020 | $55.19M | 78.38% |
| 2019 | $30.94M | 66.47% |
| 2018 | $18.59M | 29.46% |
| 2017 | $14.36M | 63.39% |
| 2016 | $8.79M | -1.08% |
| 2015 | $8.88M | -12.00% |
| 2014 | $10.09M | 132.26% |
| 2013 | $4.35M | 289.26% |
| 2012 | $1.12M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $7.87B | 4,799.19% |
US
|
|
| $4.82B | 2,899.66% |
US
|
|
| $-252.70M | -257.33% |
US
|
|
| $4.12B | 2,465.46% |
CN
|
|
| $1.66B | 932.26% |
US
|
